We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

This study is currently recruiting participants.
Verified July 2016 by Stanford University
ClinicalTrials.gov Identifier:
First Posted: July 10, 2006
Last Update Posted: July 12, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Stanford University
The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.

Condition Intervention
Carcinomas (Including Squamous Cell and Adenocarcinoma) Neoplasms Procedure: blood draw

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Biomarkers for disease [ Time Frame: Day one ]

Biospecimen Retention:   Samples Without DNA

Estimated Enrollment: 2000
Study Start Date: January 2002
Estimated Primary Completion Date: January 2022 (Final data collection date for primary outcome measure)
Detailed Description:
This is a blood serum collection study at Stanford University for patients with cancer at a variety of disease sites. The purpose of this study is to collect and store blood serum from patients before, during, and after anti-cancer therapy to find new biomarkers that signal disease or response to anti-cancer therapy. The collection and analysis of these biomarkers may lead to improved diagnostic and treatment therapies for certain cancers in the future. We are also interested in collecting blood serum from healthy individuals such as the spouses, relatives, and friends of cancer patients to obtain healthy controls for comparison

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
cancer patients
  1. Age > or = 18; for the samples collected under the NIH grant, no subjects below the age of 20 will be enrolled.
  2. Prior diagnosis of cancer or suspected of having cancer
  3. Karnofsky performance status of greater than 70
  4. Standard pretreatment evaluation
  5. Signed Stanford University Human Subjects Committee consent
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00349830

United States, California
Stanford University School of Medicine Recruiting
Stanford, California, United States, 94305
Contact: Sonya Aggarwal    650-725-4777    sonyaa@stanford.edu   
Contact: Cancer Clinical Trials Office    (650) 498-7061      
Principal Investigator: Albert Koong         
Sub-Investigator: James M Ford         
Sub-Investigator: Quynh-Thu Le         
Sub-Investigator: George Albert Fisher M.D. Ph.D.         
Sub-Investigator: Anson W Lowe         
Sponsors and Collaborators
Stanford University
Principal Investigator: Albert Koong Stanford University
  More Information

Responsible Party: Stanford University
ClinicalTrials.gov Identifier: NCT00349830     History of Changes
Other Study ID Numbers: VAR0006
77923 ( Other Identifier: Stanford University Alternate IRB Approval Number )
First Submitted: July 5, 2006
First Posted: July 10, 2006
Last Update Posted: July 12, 2016
Last Verified: July 2016

Additional relevant MeSH terms:
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type